Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

KitoTech Medical Announces First US Patent Granted on Its microMend® Wound Closure Products


KitoTech Medical, a Seattle-based medical device company, announced today that the US Patent and Trademark Office (USPTO) has issued US Patent No. 10,751,050 entitled “MICROSTRUCTURE-BASED WOUND CLOSURE DEVICES”. The patent is directed at microMend’s wound closure products, which use KitoTech’s proprietary Microstaple technology. The company has a worldwide exclusive license for this patent from the University of Washington, where the technology was initially developed. KitoTech also has an issued patent in Europe on its microMend products.

“The granting of this US patent is an important milestone for KitoTech. It provides support for the innovations, which were originally invented at the University of Washington and led to our new approach to close wounds, including lacerations and surgical incisions. The issued patent provides the foundation for our intellectual property strategy, which includes a number of additional filed patent applications on microMend and the Microstaple technology,” says Dr. Ronald Berenson, President and CEO of KitoTech Medical.

About microMend®

microMend consists of an array of miniature stainless steel staples (Microstaples) attached to an adhesive backing that combines the holding strength of a suture with the simplicity of applying a bandage. It is designed to provide medical personnel with a cost-effective, time saving and easy-to-use option for closing lacerations, skin tears, surgical incisions, and other wounds. microMend’s consumer products make it possible for people to close lacerations at home, in the outdoors or elsewhere without the inconvenience and costs associated with ER and Urgent Care Clinic visits.

About KitoTech Medical

KitoTech Medical is a medical device company spun out of the University of Washington that is using its patented Microstaples Technology platform to develop and commercialize products for wound closure and wound care. Additional product and company information can be found online at http://www.micromendskinclosure.com.

Share article on social media or email:

Foottraffik Announces AI-Powered Google Ads for Cannabis Dispensaries and Delivery Services


This software will give dispensaries a competitive advantage in their local market by maximizing their advertising spend and increasing conversions and revenue.

Foottraffik’s new AI software connects real-time trends to client Google Ads campaigns, supercharging performance and increasing revenue by up to 25%.

Using a combination of historical ecommerce transaction data, real-time weather data, and consumer social media trends, Foottraffik’s new machine learning technology creates models around a variety of rich data sets. This extensive modeling produces dynamic bid strategies that respond to trends and shifts in demand, thus yielding greater returns.

Google Ads is the most popular and most used advertising channel on the number one search engine, Google. With Google’s massive reach, the ability to leverage Google Ads for dispensaries is crucial for legitimizing the cannabis industry and increasing its visibility.

Founder and CEO Guillermo Bravo adds that, “As dispensary marketing is limited, it’s great that we can offer a highly effective and reliable marketing channel for dispensaries to reach their local customers. This software will give dispensaries a competitive advantage in their local market by maximizing their advertising spend and increasing conversions and revenue. Foottraffik is happy to announce even more functionality when it comes to launching Google Ads campaigns for dispensaries and delivery services.”

Thanks to their focus on transparency and revenue attribution, Foottraffik has been able to provide ecommerce transaction reporting on the return on investment of their Google Ads campaigns. With their new AI initiative, they will also be able to ensure that their clients’ campaigns are as successful as possible and continue to improve their effectiveness by spotting and taking advantage of trends instantly.

Headquartered in San Francisco, Foottraffik is a dispensary eCommerce growth company specializing in ROI-focused campaigns, including Google Ads, targeted mobile display ads across 3000+ mobile apps and websites, and search engine optimization exclusively for cannabis dispensaries and delivery services. They are focused on increasing revenue generation through real-time data. Foottraffik revenue attribution integrates with online menus dutchie, Jane, Weedmaps, Woo-commerce, Tymber, Blaze, and more!

Share article on social media or email:

AANP Urges All Americans to Get a Flu Vaccine Ahead of 2020-2021 Flu Season


As with COVID-19, we want to keep the flu from spreading to our most vulnerable citizens, as well as to the health care providers and essential workers who are already stretched thin during the pandemic.

As cold and influenza (flu) season approaches amid the coronavirus pandemic, the American Association of Nurse Practitioners® (AANP) urges all Americans over the age of 6 months to get a seasonal flu vaccine as soon as possible and to seek prompt attention from their health care provider if they develop flu-like symptoms.

“Given the current pandemic, it is especially important this year that people take steps to avoid getting and spreading the flu virus, and the most important step is getting a flu vaccine now,” said AANP President Sophia L. Thomas, DNP, APRN, FNP-BC, PPCNP-BC, FNAP, FAANP. “Symptoms of the flu and COVID-19 can look similar — fever, cough, body aches — so we encourage everyone to take flu prevention seriously. As with COVID-19, we want to keep the flu from spreading to our most vulnerable citizens, as well as to the health care providers and essential workers who are already stretched thin during the pandemic.”

“If you are experiencing symptoms that indicate you may have either the flu, COVID-19 or both, it is important that you seek out health care, testing and treatment immediately and not attempt to self-diagnose,” continued Thomas. “Primary care providers and clinics can do a rapid flu test that offers results in less than an hour. The best things you can do to protect yourself from illness this fall and winter are to get a flu vaccine and continue to wear a mask when in public, maintain a social distance of six feet from non-household members, wash your hands regularly and avoid touching your face.”

The flu season in the United States lasts from approximately October through March, but usually peaks between December and February, according to the Centers for Disease Control and Prevention (CDC). Flu vaccines — administered in the form of an injection or a nasal spray — are now available from health care providers across the country, as well as many pharmacies and retail or grocery store pharmacy counters. With many Americans postponing health care appointments as a result of states’ stay-at-home orders this spring, AANP is encouraging patients to speak with their health care provider to bring all needed vaccinations up to date. This will help ensure individuals and their families stay healthy. For more information about flu vaccines this year, visit the CDC’s website.

The American Association of Nurse Practitioners® (AANP) is the largest professional membership organization for nurse practitioners (NPs) of all specialties. It represents the interests of the more than 290,000 licensed NPs in the U.S. AANP provides legislative leadership at the local, state, and national levels, advancing health policy; promoting excellence in practice, education and research; and establishing standards that best serve NPs’ patients and other health care consumers. As The Voice of the Nurse Practitioner®, AANP represents the interests of NPs as providers of high-quality, cost-effective, comprehensive, patient-centered health care. To locate an NP in your community, visit to npfinder.com. For more information about NPs, visit aanp.org. For COVID-19 information from AANP, visit http://www.aanp.org/COVID19.

Share article on social media or email:

Icahn School of Medicine at Mount Sinai and Leica Microsystems Establish Center of Excellence in Microscopy


A virtual ceremony took place today to mark the occassion.

Icahn School of Medicine at Mount Sinai and Leica Microsystems, Inc. have combined efforts to establish the Leica Microsystems Center of Excellence at Icahn School of Medicine at Mount Sinai. The new Center will support a mission to drive new discoveries and insights from scientific research performed using state-of-the-art imaging systems. A virtual ceremony took place today to mark the occasion.

The Center of Excellence features cutting-edge confocal and widefield microscopy technology such as Leica SP8 STED nanoscopy imaging, allowing researchers to capture images and video of the cellular and molecular processes of life.

“The new partnership between Mount Sinai’s Microscopy and Advanced Bioimaging Core and Leica will ensure that we can meet the growing demand for novel microscopy-based instruments and strategies,” says Deanna Benson, PhD, Director of the Microscope and Advanced Bioimaging Core and Leica Microsystems Center of Excellence in Microscopy at Icahn School of Medicine at Mount Sinai. “Our partnership will also allow a free exchange of information between Leica’s application scientists and Mount Sinai’s Core facility scientists crucial for developing novel imaging strategies customized to address the wide-ranging research questions – from mechanisms of viral infection and cancer progression to cognition, stress and pain posed by our research community.“

“With this agreement, we’re enabling researchers at Icahn School of Medicine to push beyond boundaries of what can be visualized and quantified and fulfilling Leica Microsystems’ mission to provide unrivaled insight for our customers,” said Greg Eppink, General Manager, Microscopy, Leica Microsystems Americas. “We look forward to continuing this exciting alliance for years to come – it’s an honor to serve the future of scientific research in collaboration with this top-tier institution.”

“At Leica Microsystems we are actively seeking to collaborate with leading research institutions. Icahn School of Medicine scientists are world-renowned and their dedication to advancing our understanding of the mechanisms of life is truly inspiring,” said Douglas Giszczynski, Director of Academic Programs, Leica Microsystems Americas. “We at Leica Microsystems are proud that they have chosen us as collaborators on this road to discovery.”

The Center of Excellence will provide valuable feedback necessary to drive innovation in software, systems and workflow solutions while informing the applications and advanced imaging and analysis techniques of tomorrow. This supports the Leica Microsystems leitmotif of “with the user, for the user,” established by Ernst Leitz I, the entrepreneur who led the business to world renown. For 170 years, Leica Microsystems has helped shape the future and continues to do so today with its latest digital innovations enabling new insights for research, medical, and industrial applications.

The opening ceremony will be followed by virtual seminars on September 23 and 24, presented by prominent Mount Sinai researchers discussing imaging applications. Socially-distanced hands-on and virtual demonstrations of the imaging systems will be available to researchers following the seminars.

About Leica Microsystems

Leica Microsystems develops and manufactures microscopes and scientific instruments for the analysis of microstructures and nanostructures. Widely recognized for optical precision and innovative technology, the company is one of the market leaders in compound and stereo microscopy, digital microscopy, confocal laser scanning and super-resolution microscopy with related imaging systems, electron microscopy sample preparation, and surgical microscopy.

Leica Microsystems has six major plants and product development sites located in Wetzlar and Mannheim (Germany), Vienna (Austria), Heerbrugg (Switzerland), Morrisville (USA), and Singapore. The company is represented in over 100 countries, has sales and service organizations in 20 countries, and an international network of distribution partners. Its headquarters are located in Wetzlar, Germany. Leica Microsystems is part of Danaher.

About the Mount Sinai Health System

The Mount Sinai Health System is New York City’s largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai is a national and international source of unrivaled education, translational research and discovery, and collaborative clinical leadership ensuring that we deliver the highest quality care—from prevention to treatment of the most serious and complex human diseases. The Health System includes more than 7,200 physicians and features a robust and continually expanding network of multispecialty services, including more than 400 ambulatory practice locations throughout the five boroughs of New York City, Westchester, and Long Island. The Mount Sinai Hospital is ranked No. 14 on U.S. News & World Report’s “Honor Roll” of the Top 20 Best Hospitals in the country and the Icahn School of Medicine as one of the Top 20 Best Medical Schools in country. Mount Sinai Health System hospitals are consistently ranked regionally by specialty by U.S. News & World Report.

For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.

Share article on social media or email:

COVID-19 Doesn’t Appear More Severe for Patients with Chronic Rhinosinusitis


AAAAI Logo

“As we continue to fight this international pandemic, it is important researchers continue to identify risk factors for severe disease so preventative strategies can be implemented.” – Zheng Liu, MD, PhD

A study recently published in The Journal of Allergy and Clinical Immunology: In Practice (JACI: In Practice) examined the impact chronic rhinosinusitis (CRS) had on COVID-19. Results showed that patients hospitalized with COVID-19 who also had CRS had comparable complications and outcomes to patients without CRS.

Upper airway diseases like CRS, one of the most common nasal inflammatory disorders, can have a large impact on lower respiratory diseases. Despite this, the impact of CRS on COVID-19 has remained largely unknown.

Researchers retrospectively analyzed 1,172 COVID-19 patients discharged from Tongji Hospital in Wuhan, China and completed telephone follow-up within one month after discharge. Comorbidities including CRS were determined based on self-reporting by patients and confirmed independently by physicians using patient records.

In total, 6.1% of patients reported physician-diagnosed CRS. After adjusting for cofounding factors, the researchers found no significant difference in major symptoms between hospitalized COVID-19 patients with and without CRS. Additionally, researchers found no significant different between those with CRS and without when it came to the severity of COVID-19, including complications. There was no association of CRS comorbidity with disease severity on admission, mechanical ventilation, acute respiratory distress syndrome (ARDS), and hospitalization days. This suggests CRS may not modify the disease expression of COVID-19.

Zheng Liu, MD, PhD, corresponding author for this study, offered more context about the results. “Because the nasal cavity acts as a gateway to the respiratory tract, we wanted to investigate CRS to determine the likelihood of the condition being either a risk or protective factor when it came to COVID-19. As we continue to fight this international pandemic, it is important researchers continue to identify risk factors for severe disease so preventative strategies can be implemented.”

You can learn more about chronic rhinosinusitis on the American Academy of Allergy, Asthma & Immunology website, aaaai.org.

The American Academy of Allergy, Asthma & Immunology (AAAAI) represents allergists, asthma specialists, clinical immunologists, allied health professionals and others with a special interest in the research and treatment of allergic and immunologic diseases. Established in 1943, the AAAAI has more than 7,100 members in the United States, Canada and 72 other countries. The AAAAI’s Find an Allergist/Immunologist service is a trusted resource to help you find a specialist close to home.

Share article on social media or email:

Xstrahl Appoints Dr. Richard Shaffer as Medical Director


As skin cancer incidence continues to rise, we want to we further support clinicians in the use of low-dose x-ray radiation as part of a comprehensive treatment plan. Dr. Shaffer’s leadership in this area is important…

Xstrahl, the leader in superficial radiation therapy and research systems for cancer, announced today that it has appointed Richard Shaffer, FRCR, as medical director. Dr. Shaffer will help drive the clinical application of superficial and orthovoltage radiation therapy for skin cancer and benign diseases.

“As skin cancer incidence continues to rise, we want to we further support clinicians in the use of low-dose x-ray radiation as part of a comprehensive treatment plan,” said Adrian Treverton, CEO of Xstrahl. “Dr. Shaffer’s leadership in this area is important in not only increasing patient access to radiation therapy for NMSC but in also supporting its safe and effective use for other benign indications,” he added.

Dr. Shaffer has deep expertise in radiotherapy development and innovation. He currently serves as the UK lead for skin cancer and benign radiotherapy for GenesisCare UK. Clinically, he has used radiotherapy and chemotherapy to treat brain tumors, prostate and bladder cancer, and skin cancer and has additional expertise in intracranial stereotactic radiotherapy and the use of radiation for benign conditions.

“I’m excited to join with Xstrahl to help extend the use of radiation therapy not only for skin cancer but also in treating benign disease, particularly for Dupuytren’s and Ledderhose disease, Plantar Fasciitis, insertional Achilles tendinopathy, and keloid scarring,” Dr. Shaffer stated. “By bringing both clinicians and industry together, we can help more patients receive this valuable treatment,” he added.

Dr. Shaffer received his BSc in Biomedical Science from Manchester University and his MBBS from the University College of London Medical School. He formally served as chair of the radiotherapy strategy group in one of the NHS divisions prior to joining GenesisCare. Dr. Shaffer also currently serves as a consulting oncologist for BMIHealthcare and Cromwell Hospital.

# # #

For further information, please contact:

Kristie Amobi, VP of Marketing

Tel: +1-213-598-0236, e-mail: kristieamobi@xstrahl.com

Time zone: PST: Pacific Standard Time

About Xstrahl

Xstrahl is a medical technology company that designs clinical and research systems to help eradicate cancer. For more than 20 years, Xstrahl has been shaping the development of superficial and orthovoltage therapies for cancer treatment and advancing preclinical research. Xstrahl systems are in operation at more than 700 treatment and research facilities worldwide. Visit http://www.xstrahl.com to learn more.

Share article on social media or email:

FYZICAL Therapy & Balance Centers Launches Pulmonary Program to Help COVID-19 Patients Recover with Personalized Plans


With more than 400 centers spanning 45 states, FYZICAL Therapy & Balance Centers is the fastest-growing physical therapy franchise in the United States. Through a holistic, whole-body approach, FYZICAL not only helps clients to recover from injuries and surgeries, but also takes rehabilitation a step further to help clients achieve optimal wellness and regain their love of life while even learning new skills. In the midst of a global pandemic, FYZICAL’s innovative approach to health and wellness has become increasingly significant as an essential business.

When COVID-19 first hit, the FYZICAL team brought operations, headquarters team members and franchisees together to create a task force to handle challenges and support franchisees and clients. Through this, the Pulmonary Program was born.

The FYZICAL team wanted to provide proactive care to the communities that have been affected by COVID-19 throughout the U.S. The Pulmonary Program includes offering a pulmonary care guide with resources about overall treatment protocols, help with evaluations and innovative tools. The FYZICAL team brought together the best research they could find through the American Physical Therapy Association, medical resources and clinicians that had a passion for pulmonary.

Now, multiple FYZICAL locations have been participating in the Pulmonary Program and helping COVID-19 patients recover, with more than 500 team members logged into the project board.

When it comes to treatment procedures, COVID-19 is its own unique category. Patients require specialized treatment and pulmonary rehab. Since patients may be suffering from poor sleep patterns, it can lead to anxiety, depression and cognition issues. Also, patients that were in ICU units could have even further complications and their immune system could be further compromised.

“The Pulmonary Program is a comprehensive approach to care that will address the multitude of issues that can arise from dysfunctional breathing patterns caused by something as traumatic as COVID-19,” said Denise Campbell, a multi-unit FYZICAL owner and high level breathing practitioner on the brand’s COVID-19 task force. “This personalized program will help clients strengthen their breathing patterns — when breathing is healthy and balanced, it boosts the immune system and helps clients recover, both physically and emotionally.”

Typically, patients who have been receiving vestibular treatment in the past end up deconditioned because COVID-19 negatively impacts breathing. Much of FYZICAL’s expertise is already focused on improving posture, which in turn, allows patients to breathe better. “Since our centers are already well-equipped for balance issues, FYZICAL provides physical therapists access to the kind of advanced testing materials and resources needed to offer this kind of comprehensive pulmonary care,” said Campbell.

Moving forward, FYZICAL’s personalized programs that help treat an individual patient based on where they are in the recovery process. “We developed protocols and patient care because we know that those recovering from COVID-19 need to be thought of and looked at differently,” said CEO Brian Belmont. “This virus is unprecedented, so we brought in national experts that are constantly pulling together the latest information when it comes to pulmonary issues and treatments. Luckily, our clinicians are already balance experts, so we can combine that knowledge with new tools, resources and training to provide highly confident care that is COVID-19 specific and help clients achieve optimal wellness and get back to living their best life.”

About FYZICAL

FYZICAL is the fastest-growing physical therapy franchise in the United States and is headquartered in Sarasota, Florida. With more than 400 centers in 45 states, FYZICAL’s revolutionary business model is designed to optimize profitability and growth, and offers comprehensive patient care through unique balance protocols and healthy lifestyle products and services. FYZICAL is a champion of patient choice and direct access, and a leader in the future of health, wellness and preventative care. For more information on joining the FYZICAL family, visit FYZICALFranchise.com.

Share article on social media or email:

Citus Health Announces Groundbreaking Hospice Family Caregiver Research


Citus Health Hospice Family Caregiver Research

“This research delivers the roadmap for hospice providers that want to provide better communication and increase family caregiver satisfaction,” said Melissa Kozak, Co-Founder and CEO of Citus Health

Citus Health, a leading digital health solutions provider for the home-based care industry, announced the release of a first-of-its-kind study conducted in conjunction with Porter Research that captures the voice of the hospice family caregiver.

In one of the more dramatic findings, 8 out of 10 family caregivers surveyed would (1) choose one hospice over another, and (2) give that hospice higher ratings on the CAHPS hospice survey if the hospice enabled real-time communication via computer, tablet, and smart phone.

Family caregivers claim that the most popular methods – phone, text, and email – aren’t giving them the immediate response they need, and as a result 57% of survey respondents stated that hospice providers “need improvement” in four critical CAHPS survey categories.

“This research delivers the roadmap for hospice providers that want to provide better communication and increase family caregiver satisfaction,” said Melissa Kozak, Co-Founder and CEO of Citus Health. “Family caregivers demand real-time communication in the mode they prefer, whether it be on the computer, tablet, or smart phone, and will reward hospices that can deliver.”

The good news for hospice providers is that solving the communication problem is well within their control. Providers can improve the family caregiver experience through real-time communication technology that uses modern features such as secure instant messaging and video, as well as role-based auto-escalation algorithms that ensure that the proper care team member can immediately respond to patient issues.

“The Citus Health platform solution is designed to address the most important family caregiver needs through our secure instant family group messaging, video chats, customizable forms and surveys, and family caregiver education center,” says Kozak. “Plus Citus Health is device-agnostic; family caregivers can access our secure, HIPAA-compliant platform through their computer, tablet, and smartphone, and it can be done with or without an app download, depending on their preference.”

What Do Family Caregivers Say?


  • Only 43% of family caregivers report being very satisfied with their hospice providers when it comes to four publicly reported CAHPS survey questions.
  • Over 90% of family caregivers reported that the method of communication hospices use impacts four publicly-reported CAHPS survey responses.
  • 78% of family caregivers would choose a hospice that enables instant communication through computer, tablet, or mobile phone.
  • 80% of family caregivers would give hospices higher CAHPS scores if they enable instant communication through computer, tablet, or mobile phone.

Hospices that implement real-time communication technology will have a competitive advantage in the market as they become the “preferred” choice for families and receive higher CAHPS survey scores. Referral sources will recognize the higher CAHPS survey results and have the assurance that the hospice provider is investing in patient and family caregiver satisfaction.

To access the Research Report including the Roadmap for Success when it comes to family caregiver communication, click here. And to learn more about how Citus Health helps hospice providers improve family caregiver satisfaction, increase clinical staff productivity, and streamline workflows, visit http://www.citushealth.com/hospice.

About Citus Health

Citus Health offers the only completely integrated virtual patient care platform solution that removes barriers to communication to immediately improve your patient and family caregiver experience. With built in HIPAA-compliant, secure features like auto-translated multilingual instant messaging, real-time video visits, customizable forms and surveys, and a family caregiver education center, the Citus Health solution enables real time communication between your clinical staff, care partners, and family caregivers.

For more information, visit citushealth.com.

About Porter Research

Porter Research works with healthcare and IT companies to develop and execute market research programs and create strategies using market intelligence uncovered. With 30 years of experience, we have worked with more than 300 IT companies, and complete thousands of interviews each year. This means we know your industry, we know how you need to use the data, and we execute the right research program to uncover what you can’t find on your own. For more information visit http://www.porterresearch.com.

Share article on social media or email:

The Tisch Cancer Institute Earns Second Consecutive Designation from National Cancer Institute


The Tisch Cancer Institute at Mount Sinai (TCI) has been awarded $13 million as part of the renewal of its National Cancer Institute Cancer Center Designation, a prestigious distinction that is based on scientific excellence, robust clinical research, and beneficial community impact. The National Cancer Institute rated TCI’s application as “outstanding.”

The five-year redesignation award—the Institute’s second consecutive designation—will support research programs and facilities, promote collaborative translational cancer research in a coordinated manner, and help disseminate cancer research findings to the community. The funding complements $53 million in current cancer research grants earned by TCI investigators.

The strategic plan that helped lead to the redesignation this year included cutting-edge clinical research developed by teams from several disciplines, allowing TCI to provide personalized care to the New York City metro area’s diverse communities. Four areas in which TCI researchers and physicians excel, and which contributed to the redesignation, include:


  • Understanding cancer tumors and the immune system interaction on a cellular level, also known as the tumor microenvironment, a fertile area for improving cancer treatment
  • Enhancing research in genetics, gene regulation, and signaling pathways, promising areas for discoveries that will improve the lives of cancer patients
  • Elevating cancer disparities research as a means to promote equity and find better prevention and treatment strategies in the New York metro area, with a special emphasis on TCI’s neighboring communities of Central Harlem, East Harlem, and the Upper East Side
  • Disseminating TCI discoveries throughout the greater Mount Sinai network. TCI is part of an expanding cancer care network that includes seven different hospitals in New York City with more than 10,000 new cancer patients per year.

TCI was first named an NCI-designated cancer center in 2015. Since then, the recruitment of leaders in cancer genomics, lung cancer, cancer immunology, and clinical research, and the exponential growth of clinical trials originated by Mount Sinai physicians, has helped bolster the cancer center’s national prominence and continued to bring cutting-edge research from the lab to the bedside of Mount Sinai patients.

“The NCI redesignation recognizes our plan to maximize our ability to make an impact in our community and at the national level over the next five years, expanding on our successes in four key areas: cancer immunology, cancer mechanisms, cancer clinical investigation, and cancer prevention and control,” said Ramon Parsons, MD, PhD, Director of The Tisch Cancer Institute at Mount Sinai, Ward-Coleman Chair in Cancer Research, and Chair of Oncological Sciences at the Icahn School of Medicine at Mount Sinai. “Our patients are the beneficiaries of our commitment to advancing scientific research in cancer and harnessing our findings into new therapies and prevention initiatives.”

Some achievements in the four key areas include:

  • Identifying new targets in and around cancer cells to design therapies to attack those targets and kill the cancer, in the cancer clinical investigations program, which is led by Jian Jin, PhD, and Marshall Posner, MD
  • Developing cancer vaccine trials using samples of a patient’s tumor to create a personalized vaccine that would prevent cancer recurrence and that could be combined with immunotherapy for increased benefit to the patient, in the cancer immunology program, led by Nina Bhardwaj, MD, PhD, and Miriam Merad, MD, PhD
  • Researching the biology of dormant tumor cells, leading to a clinical trial in prostate cancer, in the cancer mechanisms program, led by Emily Bernstein, PhD, and Julio Aguirre-Ghiso, PhD
  • Researching whether the use of white light in bone marrow transplant and lymphoma patients improves sleep and reduces depression, in the cancer prevention and control program, led by Nina Bickell, MD, and Emanuela Taioli, MD, PhD

“Our physicians have built up a repertoire of investigator-initiated trials and novel clinical research studies, which contributed to this redesignation and has become a strength of The Tisch Cancer Institute,” said William K. Oh, MD, Deputy Director of The Tisch Cancer Institute, Chief of the Division of Hematology and Medical Oncology at the Mount Sinai Health System, and the Ezra M. Greenspan, MD, Professor in Clinical Cancer Therapeutics at the Icahn School of Medicine at Mount Sinai. “Another strength that sets us apart is our research on cancer in World Trade Center responders, due to our unique position of having a monitoring program at Mount Sinai. Our research has led to insights into how inflammation leads to cancer as well as which cancers should be investigated in this vulnerable population.”

“The Tisch Cancer Institute at Mount Sinai investigates real-world, complex medical problems and solves them with teams of scientists and physicians that successfully integrate many disciplines,” said Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine at Mount Sinai and President for Academic Affairs of the Mount Sinai Health System. “The NCI redesignation underscores our exceptional leadership, extensive research facilities, and an institution-wide commitment to research with a focus on identifying and combatting disparities so that all patients receive the best care possible.”

About the Mount Sinai Health System

The Mount Sinai Health System is New York City’s largest academic medical system, encompassing eight hospitals, a leading medical school, and a vast network of ambulatory practices throughout the greater New York region. Mount Sinai is a national and international source of unrivaled education, translational research and discovery, and collaborative clinical leadership ensuring that we deliver the highest quality care—from prevention to treatment of the most serious and complex human diseases. The Health System includes more than 7,200 physicians and features a robust and continually expanding network of multispecialty services, including more than 400 ambulatory practice locations throughout the five boroughs of New York City, Westchester, and Long Island. The Mount Sinai Hospital is ranked No. 14 on U.S. News & World Report’s ”Honor Roll” of the Top 20 Best Hospitals in the country and the Icahn School of Medicine as one of the Top 20 Best Medical Schools in country. Mount Sinai Health System hospitals are consistently ranked regionally by specialty and our physicians in the top 1% of all physicians nationally by U.S. News & World Report.

For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.

Share article on social media or email:

PlayMaker Health Announces the Launch Of Medicare Advantage Data Sets Solution


PlayMaker Health, the industry-leading post-acute sales enablement and business intelligence platform, today announced the launch of the new Medicare Advantage Data Sets with Physician and Payer Insights solution.

For the first time, home health and hospice agencies have a complete view of the most current and comprehensive Medicare Advantage claims data, featuring in-depth physician and payer insights. Within the flexible workbook, agencies sales executives and owners have the ability to:

  • Grow MA Referral Revenue: Develop new revenue streams, and capture more institutional referrals with specific MA plans by physician, region, volume, diagnosis
  • Evaluate Existing Referral Potential: By payer mix (MA, MC, VA, Medicaid), and find potential missed revenue with their MA referrals
  • Increase Agency Market Share: Get ahead of MA opportunities, and target which MA plans to contract with regionally and nationally

“As Medicare Advantage quickly gains momentum, plans are actively pursuing the partners that rely on data to deliver service in their respective market. Full visibility into the MA data sets gives home health and hospice agencies the insights they need to validate growth plans,” said Gregg Boyle, CEO of PlayMaker Health. “We are proud to have launched the industry’s first complete Medicare Advantage Data Set to equip our home health and hospice partners with the data they need to demonstrate strategic value and effectively target the right MA partnerships.”

“The level of visibility that PlayMaker’s Medicare Advantage Data Sets provides allows us to hyper-focus on which doctors have the highest Medicare mix and whether their mix is toxic,” said Lynn Ruben, Director of Customer Service and Contracting, At Home Health Care. “That level of insight prevents us from walking into a referral blind and helps avoid having to decline referrals we can’t take. The MA Data Set helps us find where the gold mines are, and narrowly focus our physician list, so we budget and spend in the right places.”

About PlayMaker Health

With 12 years of unparalleled growth for clients and partners, PlayMaker Health is proud to be the post-acute growth platform for more than 2,300 home health, hospice, HME, Infusion, and long-term care agencies and organizations nationwide. PlayMaker delivers the most comprehensive and current claims data, including Medicare Parts A and B, Medicare Advantage, Medicaid, and Commercial. By combining market data and over 35 EMR integrations with a mobile CRM, PlayMaker’s platform facilitates interoperability, turning data insights into actionable sales and growth intelligence. Learn more at https://www.playmakerhealth.com.

Share article on social media or email: